<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Myriad Genetics Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/myriad-genetics-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(QGEN) Qiagen Beats Earnings Forecasts &#8211; Reiterates Outllook</title>
		<link>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817</link>
		<comments>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99817</guid>
		<description><![CDATA[Qiagen’s (QGEN) first quarter 2012 earnings of 12 cents per share remained flat on a year-over-year basis. However, adjusting for certain one-time items, EPS came in at 23 cents in the first quarter, beating the Zacks Consensus Estimate of 19 cents as well as the year-ago quarter earnings by a couple of cents. The improvement in the bottom line was driven by double–digit sales growth and efficient cost management. In the fourth quarter, all the operational regions of the company delivered double-digit growth at CER. Region wise, Americas (47% of revenues) witnessed a 15% increase in sales at CER, driven by strong contributions from the US, Brazil and Canada. However, revenues from Europe- Middle East-Africa (34% of sales) and Asia-Pacific /Japan (18% of sales) increased 12% and 18% at CER, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Inks Deal with Cephalon</title>
		<link>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439</link>
		<comments>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:53:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97439</guid>
		<description><![CDATA[The recent agreement with Cephalon is another attempt by Myriad Genetics (MYGN) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals (TEVA).  Under the agreement, Myriad will conduct BRCA1 and BRCA2 mutation testing on patients with Bracanalysis before being enrolled in a phase I/II clinical study. Over the recent past, the company has entered into similar agreements with players such as Abbott (ABT), Astra Zeneca (AZN) and BioMarin Pharmaceuticals (BMRN) to provide companion diagnostic tests for clinical trial enrollment. Bracanalysis is Myriad’s flagship product, which analyzes the BRCA1 and BRCA2 genes to assess a woman&#8217;s risk for hereditary breast and ovarian cancer. Moreover, the acquisition of RBM (Rules-Based Medicine), made in 2011 would better place Myriad in this arena on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Expands with New Deals</title>
		<link>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111</link>
		<comments>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:09:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90111</guid>
		<description><![CDATA[In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration with the Tennessee-based molecular diagnostics company Insight Genetics, Qiagen will provide a genetic test with a biomarker for non-small cell lung cancers (NSCLC) that express the abnormal anaplastic lymphoma kinase (ALK) gene. Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen’s 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. With the companion diagnostics market expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform</title>
		<link>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154</link>
		<comments>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:39:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78154</guid>
		<description><![CDATA[Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion into Europe. With respect to new products, Myriad aims to launch at least one new molecular diagnostic product each year. The company’s tenth product, slated for launch in the second half of 2011, will assist dermatopathologists in determining whether a patient’s mole is benign or a malignant melanoma. We are also encouraged by Myriad’s recent acquisition of Texas based, privately-held Rules-Based Medicine (RBM) for $80 million in cash. This deal would expand the company’s portfolio to take into its ambit psychiatric disorders, infectious diseases and inflammatory diseases. According to Myriad, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-analyst-uprades-shares-to-outperform/78154/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-bull-of-the-day/78160</link>
		<comments>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-bull-of-the-day/78160#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:39:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78160</guid>
		<description><![CDATA[Myriad Genetics&#8217; (MYGN) flagship product, Bracanalysis, has been recording robust growth over the past few quarters. Moreover, the company is undertaking strategies to expand the scope of the test. A strong cash balance enables the company to buyback shares, expand into new markets and introduce more products. Moreover, the acquisition of RMB will help diversify Myriad&#8217;s diagnostics portfolio and further strengthen its position in the companion diagnostics space. The company&#8217;s strategy of expanding into Europe is also encouraging. Although the economic environment has improved, any hiccup in the recovery process will be a dampener for the stock. Based on the strong growth potential of Myriad, we upgrade the stock to Outperform. MYRIAD GENETICS (MYGN): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/mygn-myriad-genetics-bull-of-the-day/78160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANGO) Company News for June 16, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/06/16/ango-company-news-for-june-16-2011-corporate-summary/76538</link>
		<comments>http://www.stockbloghub.com/2011/06/16/ango-company-news-for-june-16-2011-corporate-summary/76538#comments</comments>
		<pubDate>Thu, 16 Jun 2011 15:20:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[Ceradyne Inc.]]></category>
		<category><![CDATA[CRDN]]></category>
		<category><![CDATA[General Mills Inc.]]></category>
		<category><![CDATA[GIS]]></category>
		<category><![CDATA[Hospitality Properties Trust]]></category>
		<category><![CDATA[HPT]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[K]]></category>
		<category><![CDATA[Kellogg Company]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[OI]]></category>
		<category><![CDATA[Owens-Illinois Inc.]]></category>
		<category><![CDATA[SMG]]></category>
		<category><![CDATA[The Scotts Miracle-Gro Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76538</guid>
		<description><![CDATA[•    Share prices of Scotts Miracle-Gro Company (NYSE:SMG) dipped 6.02% after the company reduced its earnings estimate for the fiscal year 2011 •    Shares of Owens-Illinois (NYSE:OI) dropped 13.54% to close at $25.54 after the company said its second quarter earnings figures could fall due to a jump in manufacturing and delivery expenses •    Johnson &#38; Johnson (NYSE:JNJ) is reportedly pulling out of the drug-coated heart stent market because of continually declining sales. The global market for this segment is valued at $4 billion •    Analysts at Jefferies &#38; Co. initiated coverage on shares of General Mills, Inc. (NYSE:GIS) with &#8220;Hold&#8221; rating and a target price of $40 •    Analysts at Jefferies &#38; Co. initiated coverage on Shares of Kellogg (NYSE:K) with &#8220;Underperform&#8221; rating and also lowered the target price ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/ango-company-news-for-june-16-2011-corporate-summary/76538/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing</title>
		<link>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983</link>
		<comments>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:13:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70983</guid>
		<description><![CDATA[Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of genetically defined cancers. Bracanalysisis Myriad’s flagship product, contributing 89% of total revenue. This test provides a comprehensive analysis of BRCA1 and BRCA2 genes for assessing woman&#8217;s risk of hereditary breast and ovarian cancers. Under the agreement, the company will carry out Bracanalysis test to identify the presence of germline mutations in the patients prior to enrollment in the study. Accordingly, it will provide standard test reports to the clinicians. Myriad is aiming at establishing itself as a strong player in the companion diagnostic market. To establish ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HUM) June 2010 &#8211; Industry Outlook &#8211; Health Care Stock Review</title>
		<link>http://www.stockbloghub.com/2010/06/03/hum-june-2010-industry-outlook-health-care-stock-review/39181</link>
		<comments>http://www.stockbloghub.com/2010/06/03/hum-june-2010-industry-outlook-health-care-stock-review/39181#comments</comments>
		<pubDate>Thu, 03 Jun 2010 13:12:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIOS]]></category>
		<category><![CDATA[BioScrip Inc.]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[Tenet Healthcare Corporation]]></category>
		<category><![CDATA[THC]]></category>
		<category><![CDATA[UIS]]></category>
		<category><![CDATA[Unisys Corporation]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=39181</guid>
		<description><![CDATA[The health care sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful of the different drivers and appropriate metrics associated with the various sub-sectors. In March 2010, U.S. healthcare reform passed through Congress, which aims to expand coverage to 31 million Americans who are currently uninsured. This translates into 31 million more customers for the health insurance industry, and 31 million more people for whom prescriptions might be written. Furthermore, the bill cracks down on insurance company abuses. There are multiple pilot programs in the bill that have the potential to significantly reduce the growth in health care costs. However, most of the provisions of the bill ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/03/hum-june-2010-industry-outlook-health-care-stock-review/39181/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/05/23/mygn-myriad-genetics-bear-of-the-day-2/37635</link>
		<comments>http://www.stockbloghub.com/2010/05/23/mygn-myriad-genetics-bear-of-the-day-2/37635#comments</comments>
		<pubDate>Mon, 24 May 2010 04:26:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37635</guid>
		<description><![CDATA[Myriad Genetics Inc.&#8217;s (MYGN) third quarter fiscal 2010 earnings of $0.33 per share fell short of the Zacks Consensus Estimate by $0.05. The company had earned $0.38 per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business is performing well, we remain concerned about the overall weakness in the economy. It has affected sales adversely in recent quarters. The competition confronting Myriad Genetics&#8217; products in the biotechnology and genetics testing field is also a concern. Consequently, we downgrade the stock to Underperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/23/mygn-myriad-genetics-bear-of-the-day-2/37635/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Surpasses Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/04/mygn-myriad-surpasses-consensus-estimates/26894</link>
		<comments>http://www.stockbloghub.com/2010/02/04/mygn-myriad-surpasses-consensus-estimates/26894#comments</comments>
		<pubDate>Thu, 04 Feb 2010 22:59:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26894</guid>
		<description><![CDATA[Myriad Genetics Inc. (MYGN) reported second quarter fiscal 2010 earnings of 36 cents per share, two cents above the Zacks Consensus Estimate. The company had earned 22 cents in the year-ago period. The year-ago earnings were inclusive of a loss of $15.6 million from discontinued operations pertaining to Myriad’s former research and pharmaceutical businesses. Detailed Quarterly Results Myriad posted a net profit of $35.4 million, which represented a 67% rise from the year-ago quarter. This increase in profitability was attributable to the company’s improved gross profit margin in the reported quarter of 88% as against 87% in the first quarter of fiscal 2010. Molecular diagnostic revenues for the quarter came in at $92.8 million as against $84.0 million in the prior-year quarter, a 10.5% increase. The improvement was attributable primarily ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/04/mygn-myriad-surpasses-consensus-estimates/26894/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics Upgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2009/12/17/mygn-myriad-genetics-upgraded-to-neutral/23104</link>
		<comments>http://www.stockbloghub.com/2009/12/17/mygn-myriad-genetics-upgraded-to-neutral/23104#comments</comments>
		<pubDate>Thu, 17 Dec 2009 18:42:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23104</guid>
		<description><![CDATA[We have upgraded Myriad Genetics (MYGN) to Neutral from Underperform based on the impressive performance of its molecular diagnostics business. Effective July 1, 2009, the company spun off its therapeutics business to focus on molecular diagnostics. We believe that the de-risking strategy to separate the profitable predictive medicine business from the higher risk drug development business will create better value for shareholders. Each company will be able to pursue its long-term strategic initiatives, maximize its core technology strengths, seek new product opportunities, have a capital structure appropriate for its financial profile, and compete more effectively in its respective markets. Sales of Myriad Genetics’ molecular diagnostic products continued to grow impressively in the first quarter of fiscal 2010. Sales came in at $85.1 million, versus $70.0 million for the same period ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/mygn-myriad-genetics-upgraded-to-neutral/23104/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2009/11/16/mygn-myriad-genetics-bear-of-the-day/20657</link>
		<comments>http://www.stockbloghub.com/2009/11/16/mygn-myriad-genetics-bear-of-the-day/20657#comments</comments>
		<pubDate>Mon, 16 Nov 2009 18:22:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20657</guid>
		<description><![CDATA[Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business is performing well, we remain concerned about the slowdown in revenue growth in recent quarters. The competition confronting Myriad Genetics products in the biotechnology and genetics testing field is also a concern. We have an Underperform rating on the stock. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/16/mygn-myriad-genetics-bear-of-the-day/20657/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics Inc Misses Forecasts by a Penny</title>
		<link>http://www.stockbloghub.com/2009/11/08/mygn-myriad-genetics-inc-misses-forecasts-by-a-penny/19880</link>
		<comments>http://www.stockbloghub.com/2009/11/08/mygn-myriad-genetics-inc-misses-forecasts-by-a-penny/19880#comments</comments>
		<pubDate>Mon, 09 Nov 2009 03:23:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19880</guid>
		<description><![CDATA[Myriad Genetics Inc. (MYGN) reported fiscal first-quarter earnings of 31 cents per share, a penny behind the Zacks Consensus Estimate. The company had earned 25 cents in the year-ago period. Molecular diagnostic revenues for the quarter came in at $85.12 million as against $69.97 million in the prior-year quarter, a 21.6% increase. The improvement was attributable mainly to Myriad&#8217;s increased sales and marketing efforts. However, revenue growth has slowed in the recent quarters due to the recession. Myriad has undertaken several measures Incorporatedluding adding new sales representatives, to reinvigorate sales. Gross profit for the quarter came in at $74.1 million, or 87% of molecular diagnostic revenues, as against $60.2 million, or 86% of molecular diagnostic revenues last year. The margin growth was primarily attributable to improvements in technology coupled with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/mygn-myriad-genetics-inc-misses-forecasts-by-a-penny/19880/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents Estimate</title>
		<link>http://www.stockbloghub.com/2009/08/26/mygn-myriad-reports-strong-earnings-of-37-cents-vs-23-cents-estimate/13446</link>
		<comments>http://www.stockbloghub.com/2009/08/26/mygn-myriad-reports-strong-earnings-of-37-cents-vs-23-cents-estimate/13446#comments</comments>
		<pubDate>Wed, 26 Aug 2009 16:09:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[Myriad Pharmaceuticals Inc]]></category>
		<category><![CDATA[MYRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13446</guid>
		<description><![CDATA[Yesterday, Myriad Genetics Inc. (MYGN) reported fourth quarter earnings of 37 cents per share from continuing operations. This was well above the Zacks Consensus Estimate of 23 cents. For fiscal year 2009, the company earned $1.38 per share from continuing operations. Molecular Diagnostic Revenues for the quarter came in at $86.1 million, versus $64.7 million for the same period of the prior year, thus reflecting a 33% increase. Fiscal 2009 saw a 47% increase in revenues to $326.5 million from $222.9 million in the year-ago period. The improvement was attributable mainly to Myriad&#8217;s increased sales and marketing efforts, which have created higher demand for the company&#8217;s molecular diagnostic products. However, revenue growth slowed down during the second half due to the recession. Myriad has undertaken several measures Incorporatedluding adding 50 new ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/26/mygn-myriad-reports-strong-earnings-of-37-cents-vs-23-cents-estimate/13446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Biotech Industry &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2009/06/01/mygn-biotech-industry-zacks-analyst-interviews/7669</link>
		<comments>http://www.stockbloghub.com/2009/06/01/mygn-biotech-industry-zacks-analyst-interviews/7669#comments</comments>
		<pubDate>Mon, 01 Jun 2009 23:05:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DCGN]]></category>
		<category><![CDATA[deCODE genetics Inc.]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=7669</guid>
		<description><![CDATA[OVERVIEW The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies), while the Dow Jones Biotech Index declined 3% (which includes 33 companies). At the same time, both the NASDAQ Composite and S&#38;P 500 have achieved positive returns. NASDAQ has made a gain of 11% as of 5/26/09 and the S&#38;P 500 has gained 0.8%, while the Dow Jones Industrials reached a negative 3.5% return. This constitutes a sharp contrast with last year when the Biotech industry as a whole achieved much better performance than the market. In 2008, all three biotech ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/01/mygn-biotech-industry-zacks-analyst-interviews/7669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics, Inc. &#8211; Momentum &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/03/16/mygn-myriad-genetics-inc-momentum-zacks-rank-buy/4369</link>
		<comments>http://www.stockbloghub.com/2009/03/16/mygn-myriad-genetics-inc-momentum-zacks-rank-buy/4369#comments</comments>
		<pubDate>Mon, 16 Mar 2009 22:46:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4369</guid>
		<description><![CDATA[Myriad Genetics, Inc. (MYGN) continues to head higher after the company reported strong earnings on Feb 3 and announced a 2-for-1 stock split on Feb 24. Second-Quarter Results Much of Myriad&#8217;s recent price strength is built upon the company&#8217;s solid second-quarter results. Revenue was up an impressive 49% from last year to $84.4 million. Profit was also up big, jumping to $21.2 million from a loss of $5.1 million last year. Earnings came in at 43 cents per share, 10 cents ahead of the consensus estimate. Myriad has surprised and beat the consensus in each of the last 3 quarters, showing a knack for growing its earnings in a tough environment. Estimates After the good quarter, estimates ticked higher, with the current-year advancing 4 cents to $1.73 per share. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/16/mygn-myriad-genetics-inc-momentum-zacks-rank-buy/4369/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics &#8211; Revenues increased 58%, on a year-over-year basis</title>
		<link>http://www.stockbloghub.com/2009/02/10/mygn-myriad-genetics-revenues-increased-58-on-a-year-over-year-basis/2655</link>
		<comments>http://www.stockbloghub.com/2009/02/10/mygn-myriad-genetics-revenues-increased-58-on-a-year-over-year-basis/2655#comments</comments>
		<pubDate>Tue, 10 Feb 2009 19:54:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2655</guid>
		<description><![CDATA[Myriad Genetics, Inc. (MYGN) has just reported a fantastic quarter and shares have responded. Analysts are responding with sharp increases in earnings estimates. Company Description Myriad Genetics uses gene-based medicine to develop therapeutic and molecular diagnostic products. The company employs a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. The company has integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled it to identify numerous proteins as targets for new drugs and molecular diagnostic tests. Revenues Up 58% Myriad reported second-quarter results for fiscal 2009 on Feb 3 that included revenues of $84 million. Revenues increased 58%, on a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/10/mygn-myriad-genetics-revenues-increased-58-on-a-year-over-year-basis/2655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics &#8211; Revenue increased 53% from last year</title>
		<link>http://www.stockbloghub.com/2009/01/14/mygn-myriad-genetics-revenue-increased-53-from-last-year/2090</link>
		<comments>http://www.stockbloghub.com/2009/01/14/mygn-myriad-genetics-revenue-increased-53-from-last-year/2090#comments</comments>
		<pubDate>Thu, 15 Jan 2009 01:33:44 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2090</guid>
		<description><![CDATA[Myriad Genetics, Inc.&#8217;s (MYGN) share price continues to advance after the company reported a great quarter in early November. Analysts are bullish on the company, with the next-year estimate projecting 60% earnings growth. Company Description Myriad Genetics is a healthcare company that develops molecular diagnostic and therapeutic products. Its products include items to asses a persons risk for developing various forms of cancer. Myriad has a market cap of $3.15 billion. First-Quarter Results Myriad stepped up and reported impressive first-quarter results on Nov 4 that were ahead of analyst estimates. Revenue increased 53% from last year to $73.6 million. Income surged higher, up to $14.5 million from a loss of $8 million last year. This produced earnings of 30 cents per share, more than double analyst estimates of 14 cents. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/01/14/mygn-myriad-genetics-revenue-increased-53-from-last-year/2090/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

